Harrow (NASDAQ:HROW) Reaches New 1-Year High at $44.90

Harrow, Inc. (NASDAQ:HROW)’s share price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $44.90 and last traded at $44.51, with a volume of 154554 shares. The stock had previously closed at $42.07.

Wall Street Analyst Weigh In

HROW has been the topic of several recent research reports. Lake Street Capital increased their target price on shares of Harrow from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, June 3rd. Craig Hallum increased their price target on shares of Harrow from $30.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, B. Riley reissued a “buy” rating and set a $50.00 price target on shares of Harrow in a research report on Thursday, August 29th.

Harrow Stock Up 8.1 %

The stock has a market capitalization of $1.61 billion, a PE ratio of -49.01 and a beta of 0.75. The company has a current ratio of 2.60, a quick ratio of 2.43 and a debt-to-equity ratio of 3.18. The company’s 50-day moving average is $32.06 and its 200 day moving average is $20.47.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.12. The firm had revenue of $48.94 million during the quarter, compared to analyst estimates of $42.78 million. Harrow had a negative net margin of 21.78% and a negative return on equity of 40.59%. As a group, analysts anticipate that Harrow, Inc. will post -0.38 EPS for the current year.

Hedge Funds Weigh In On Harrow

Hedge funds and other institutional investors have recently bought and sold shares of the business. Franklin Resources Inc. increased its holdings in Harrow by 27.9% in the 4th quarter. Franklin Resources Inc. now owns 294,221 shares of the company’s stock worth $3,295,000 after buying an additional 64,252 shares during the period. Vanguard Group Inc. increased its holdings in Harrow by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company’s stock worth $24,208,000 after buying an additional 21,253 shares during the period. Woodmont Investment Counsel LLC increased its holdings in Harrow by 73.3% in the 1st quarter. Woodmont Investment Counsel LLC now owns 211,579 shares of the company’s stock worth $2,799,000 after buying an additional 89,510 shares during the period. Private Capital Management LLC increased its holdings in Harrow by 7.8% in the 1st quarter. Private Capital Management LLC now owns 3,012,393 shares of the company’s stock worth $39,854,000 after buying an additional 217,896 shares during the period. Finally, Stifel Financial Corp increased its holdings in Harrow by 27.0% in the 4th quarter. Stifel Financial Corp now owns 431,973 shares of the company’s stock worth $4,838,000 after buying an additional 91,881 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.